GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Intec Pharma Ltd (XTAE:NTEC) » Definitions » Debt-to-EBITDA

Intec Pharma (XTAE:NTEC) Debt-to-EBITDA : -0.05 (As of Mar. 2021)


View and export this data going back to 2010. Start your Free Trial

What is Intec Pharma Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Intec Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2021 was ₪2.16 Mil. Intec Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2021 was ₪0.66 Mil. Intec Pharma's annualized EBITDA for the quarter that ended in Mar. 2021 was ₪-54.40 Mil. Intec Pharma's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2021 was -0.05.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Intec Pharma's Debt-to-EBITDA or its related term are showing as below:

XTAE:NTEC's Debt-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 1.31
* Ranked among companies with meaningful Debt-to-EBITDA only.

Intec Pharma Debt-to-EBITDA Historical Data

The historical data trend for Intec Pharma's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intec Pharma Debt-to-EBITDA Chart

Intec Pharma Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Debt-to-EBITDA
Get a 7-Day Free Trial - - - -0.04 -0.07

Intec Pharma Quarterly Data
Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.09 -0.10 -0.08 -0.07 -0.05

Competitive Comparison of Intec Pharma's Debt-to-EBITDA

For the Biotechnology subindustry, Intec Pharma's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Intec Pharma's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Intec Pharma's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Intec Pharma's Debt-to-EBITDA falls into.



Intec Pharma Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Intec Pharma's Debt-to-EBITDA for the fiscal year that ended in Dec. 2020 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(2.22 + 1.259) / -47.021
=-0.07

Intec Pharma's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2021 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(2.164 + 0.663) / -54.404
=-0.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2021) EBITDA data.


Intec Pharma  (XTAE:NTEC) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Intec Pharma Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Intec Pharma's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Intec Pharma (XTAE:NTEC) Business Description

Traded in Other Exchanges
N/A
Address
12 Hartom Street, Har Hotzvim, Jerusalem, ISR, 9777512
Intec Parent Inc, formerly Intec Pharma Ltd is a clinical-stage biopharmaceutical company based in Israel. The company is focused on research and development and clinical trials. The company develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. Accordion Pill is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing efficient gastric retention. Accordion Pill Carbidopa/Levodopa or AP-CDLD is being developed by the company for the indication of treatment of Parkinson's disease.